Valirx (VAL)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

12.75p
   
  • Change Today:
      0.75p
  • 52 Week High: 55.25
  • 52 Week Low: 10.50
  • Currency: UK Pounds
  • Shares Issued: 90.17m
  • Volume: 2,494,182
  • Market Cap: 11.50m
  • RiskGrade: 435

Valirx Overview

ValiRx accelerates the development of treatments in cancer and womens health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn n/a n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue n/a n/a
Pr/Book 3.4  
Latest F'cast
Revenue n/a n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Valirx Fundamentals

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-17 n/a (3.55) (237.50)p n/a n/a n/a n/a 0.0%
31-Dec-18 n/a (4.83) (117.50)p n/a n/a n/a n/a 0.0%
31-Dec-19 n/a (2.72) (4,135.00)p n/a n/a n/a n/a 0.0%
31-Dec-20 n/a (1.54) (3.81)p n/a n/a n/a n/a 0.0%
31-Dec-21 n/a (1.68) (2.34)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Valirx Forecasts

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-22 n/a (1.63) (2.19)p n/a n/a n/a n/a 0.0%
31-Dec-23 n/a n/a n/a n/a n/a n/a n/a 0.0%

Copyright © 2022 FactSet Research Systems Inc. All rights reserved.

Valirx Company Announcements

Holding(s) in Company 14-Jul-2022 10:46 RNS
Successful evaluation of breast cancer programme 13-Jul-2022 14:15 RNS
Director/PDMR Shareholding 07-Jul-2022 11:07 RNS

Latest Valirx Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

Valirx Market Data

Currency UK Pounds
Share Price 12.75p
Change Today 0.75p
% Change 6.25 %
52 Week High 55.25
52 Week Low 10.50
Volume 2,494,182
Shares Issued 90.17m
Market Cap 11.50m
RiskGrade 435

Valirx Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
38.6% below the market average38.6% below the market average38.6% below the market average38.6% below the market average38.6% below the market average
7.14% below the sector average7.14% below the sector average7.14% below the sector average7.14% below the sector average7.14% below the sector average
Price Trend
49.05% below the market average49.05% below the market average49.05% below the market average49.05% below the market average49.05% below the market average
6.25% below the sector average6.25% below the sector average6.25% below the sector average6.25% below the sector average6.25% below the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Valirx Dividends

No dividends found

Trades for 11-Aug-2022

Time Volume / Share Price
17:06 36,660 @ 12.75p
16:28 75,000 @ 12.95p
16:27 700,000 @ 12.70p
16:12 154 @ 12.92p
16:12 25,000 @ 12.92p

Valirx Key Personnel

CFO Gerald Desler
CEO Suzanne Dilly

Top of Page